MENU
+Compare
URGN
Stock ticker: NASDAQ
AS OF
Apr 4, 12:29 PM (EDT)
Price
$10.46
Change
-$0.07 (-0.66%)
Capitalization
485.83M

URGN UroGen Pharma Ltd Forecast, Technical & Fundamental Analysis

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers... Show more

Industry: #Biotechnology
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for URGN with price predictions
Apr 03, 2025

URGN in upward trend: 10-day moving average crossed above 50-day moving average on March 18, 2025

The 10-day moving average for URGN crossed bullishly above the 50-day moving average on March 18, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 141 cases where URGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for URGN moved out of overbought territory on March 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on URGN as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for URGN turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

URGN moved below its 50-day moving average on April 03, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

URGN broke above its upper Bollinger Band on March 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. URGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.234) is normal, around the industry mean (13.581). P/E Ratio (0.000) is within average values for comparable stocks, (64.662). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.879). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (5.000) is also within normal values, averaging (248.206).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. URGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

URGN is expected to report earnings to fall 1.68% to -78 cents per share on May 08

UroGen Pharma Ltd URGN Stock Earnings Reports
Q1'25
Est.
$-0.79
Q4'24
Missed
by $0.03
Q3'24
Beat
by $0.27
Q2'24
Missed
by $0.08
Q1'24
Missed
by $0.10
The last earnings report on March 10 showed earnings per share of -80 cents, missing the estimate of -76 cents. With 118.84K shares outstanding, the current market capitalization sits at 485.83M.
A.I. Advisor
published General Information

General Information

a developer of therapies for urological pathologies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Alexander Park Drive
Phone
+1 646 768-9780
Employees
201
Web
https://www.urogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCCVX32.97N/A
N/A
Fidelity Advisor Convertible Secs C
MRFIX57.60N/A
N/A
MFS Research I
PQNAX25.54N/A
N/A
Virtus NFJ Mid-Cap Value A
GALPX21.36N/A
N/A
Goldman Sachs U.S. Equity ESG P
FEGKX13.39N/A
N/A
Fidelity Equity Growth K6

URGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with CYYNF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then CYYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-5.98%
CYYNF - URGN
38%
Loosely correlated
N/A
MREO - URGN
34%
Loosely correlated
-6.75%
IDYA - URGN
33%
Poorly correlated
-4.77%
IMNM - URGN
33%
Poorly correlated
-7.00%
TRDA - URGN
32%
Poorly correlated
-8.86%
More